Skip to main content
SpringerLink
Log in

Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Vorozole (RivizorTM), is a triazole derivative and one of the new, third generation aromatase inhibitors. Vorozole causes reversible inhibition of cytochrome P450 aromatase with the majority of the aromatase inhibition activity attributable to the dextro-isomer. In vitro the IC50 against human placental aromatase and in cultured rat ovarian granulosa cells is 1.38 and 0.44 nM, respectively. Vorozole is selective and does not effect other cytochrome P450-dependent reactions at concentrations up to at least 500-fold the aromatase inhibiting concentration. In vitro vorozole, at concentrations of up to 10 μM, does not exhibit agonistic or antagonistic effects on steroid receptors including the estrogen, progestin, androgen and glucocorticoid receptors. In vivo vorozole produces dose-dependent inhibition of aromatase and reduces circulating estrogen levels. Vorozole has been shown to inhibit intratumoral aromatase activity in postmenopausal breast cancer patients pretreated for 7 days prior to undergoing mastectomy. Tissue estrone and estradiol levels were also shown to be decreased by 64% and 80%, respectively. In four phase II clinical trials, vorozole produced response rates of 18–33% corresponding to selective inhibition of estradiol. Vorozole has been examined in large, randomized multi-centre, controlled trials against both megestrol acetate (MA) and aminoglutethimide (AG) plus hydrocortisone. Against MA, response rates were comparable (10.5% vorozole; 7.6% MA) however, a trend towards improvement in median duration of response for vorozole (18.2 versus 12.5 months; p=0.07) was shown. No differences in time to progression or survival were noted. Significant and persistent weight gain associated with MA administration was the most notable difference in tolerability between the two agents. Against AG, vorozole showed a higher response rate (23% versus 18%) however this did not reach statistical significance (p=0.085). No differences in duration of response, time to progression and survival were noted. A significantly better Functional Living Index-Cancer (FLIC) quality of life score was associated with vorozole compared to AG. Vorozole is a specific, selective and potent aromatase inhibitor and useful for postmenopausal patients with advanced breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wouters W, De Coster R, Van Dun J et al.: Comparative effects of the aromatase inhibitor R76713 and of its enantiomers R83839 and R83842 on steroid biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol 37: 1049–1054, 1990

    Article  PubMed  CAS  Google Scholar 

  2. Vanden Bossche H, Willemsens G, Roels I et al.: R76713 and enantiomers selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis. Biochem Pharmacol 40: 1707–1718, 1990

    Article  PubMed  CAS  Google Scholar 

  3. Wouters W, De Coster R, Beerens D et al.: Potency and selectivity of the aromatase inhibitor R76713. A study in human ovarian, adipose stromal, testicular and adrenal cells. J Steroid Biochem 36: 57–65, 1990

    Article  PubMed  CAS  Google Scholar 

  4. Vorozole (R083842) Investigator's Brochure. Third edition, May 1995

  5. De Coster R, Wouters W, Bowden CR et al.: New non-steroidal aromatase inhibitors: focus on R76713. J Steroid Biochem Molec Biol 37: 335–341, 1990

    Article  PubMed  CAS  Google Scholar 

  6. Dowsett M, Stein RC, Mehta A et al.: Polency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol 32: 623–634, 1990

    CAS  Google Scholar 

  7. Wouters W, De Coster R, Krekels M et al.: R76713, a new specific non-steroidal aromatase inhibitor. J Steroid Biochem 32: 781–788, 1989

    Article  PubMed  CAS  Google Scholar 

  8. Wouters W, Van Ginckel R, Krekels M et al.: Pharmacology of vorozole. J Steroid Biochem Molec Biol 44: 617–621, 1993

    Article  PubMed  CAS  Google Scholar 

  9. Tuman RW, Morris DM, Wallace NM et al.: Inhibition of peripheral aromatization in the male cynomologus monkey by a novel nonsteroidal aromatase inhibitor (Ro76713). J Clin Endocrinol Metab 72: 755–760, 1991

    Article  PubMed  CAS  Google Scholar 

  10. Hoggins C, Grand LC, Brillantes FP: Mammary cancer induced by a simple feeding of polynuclear hydrocarbons and its suppression. Nature 4760: 204–220, 1961

    Article  Google Scholar 

  11. Rose DW, Pruitt B, Stauber P et al.: Influence of dosage schedule on the biological characteristics of N-nitrosomethylurea-induced rat mammary tumors, Cancer Res 40: 235–239, 1980

    PubMed  CAS  Google Scholar 

  12. De Coster R, Van Ginckel RF, Callens MJL et al.: Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res 52: 1240–1244, 1992

    PubMed  CAS  Google Scholar 

  13. van der Wall E, Donker TH, de Frankrijker E et al.: Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res 53: 4563–4566, 1993

    PubMed  CAS  Google Scholar 

  14. de Jong PC, van de Ven J, Nortier HWR et al.: Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res 57: 2109–2111, 1997

    PubMed  CAS  Google Scholar 

  15. Johnston SRD, Smith IE, Doody E et al.: Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 54: 5875–5881, 1994

    PubMed  CAS  Google Scholar 

  16. Goss PE, Clark RM, Ambus U et al.: Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res 1: 287–294, 1995

    PubMed  CAS  Google Scholar 

  17. Goss PE, Walde D, De Coster R et al.: Rivizor — a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure. Manuscript submitted

  18. Patidaens R, Piccart M, Nooij M et al.: Phase II study of vorozole (R83842), a new non-steroidal aromatase inhibitor, in advanced breast cancer. EORTC Breast Cancer Cooperative Group [abstract]. Eur J Cancer A 30ASuppl 2: 23, 1994

    Google Scholar 

  19. Iscobelli S, Boccardo F, Amoroso D et al.: Phase 2 study with vorozole as 2nd line treatment of post-menopausal patients with advanced breast cancer: preliminary results of a multicentred study [in Italian] [abstract]. Tumori 31:80 Suppl 80, 1994

    Google Scholar 

  20. Goss P, Winer E, Tannock I et al.: Vorozole versus Megace® in postmenopausal women with metastatic breast carcinoma who had relapsed following tamoxifen. Proc Am Soc Clin Oncol 33: 155a (Abstract No. 542), 1997

    Google Scholar 

  21. Bergh J, Bonneterre J, Illiger HJ et al.: Vorozole (Rivizor™) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen. Proc Am Soc Clin Oncol 33: 155a (Abstract No. 543), 1997

    Google Scholar 

Download references

Authors
  1. Paul E. Goss
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goss, P.E. Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor. Breast Cancer Res Treat 49 (Suppl 1), S59–S65 (1998). https://doi.org/10.1023/A:1006052923468

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006052923468

Search

Navigation